Opendata, web and dolomites

NOC

Nerve-on-Chips

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOC project word cloud

Explore the words cloud of the NOC project. It provides you a very rough idea of what is the project "NOC" about.

65    chips    competitors    tri    patients    neuron    2020    total    neurodegenerative    3d    supply    drugs    agencies    physiological    grow    founded    biology    assessing    licenses    care    organ    independence    worldwide    incidence    relatives    individuals    feasibility    life    subunits    share    biopharmaceutical    lives    patented    memories    cureor    biotech    few    functions    market    mbbt    clients    microfluidic    generate    million    time    innovative    models    biological    advantages    expectancy    function    burden    types    noc    lose    ooc    diseases    animal       prevent    human    microbrain    2014    vitro    policy    people    turn    competitiveness    chain    compatibility    ip    culture    society    suffer    networks    economic    simulate    visualization    start    ultimately    provides    financial    clinical    2d    nerve    improvement       startup    worth    reconstitution    alzheimer    trillion    technological    purchase    individual    health    micron    absence    drug    dimensional    patent    coming    reconstructed    readouts    turnover    tissues    organoids    subcategory    solutions    disease    efficiency    devastating    conventional    nd    latter    shape    15    reduce    predicting    validating   

Project "NOC" data sheet

The following table provides information about the project.

Coordinator
MICROBRAIN BIOTECH 

Organization address
address: 46 RUE CARDINET
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://microbrainbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICROBRAIN BIOTECH FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Neurodegenerative diseases (“ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).

MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (“NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models: - Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness) - Reduce animal testing - Predicting human-relevant drug responses - Compatibility with readouts used in biology & real time visualization - Reconstitution of complex organ-level physiological functions

NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More